secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001558370-23-008652
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics Q1 net income $124M on $150.5M collaboration revenue; cash $273.3M
--------------------------------------------------------------------------------

- Net income of $124.0M in Q1 2023 vs net loss of $21.3M in Q1 2022; collaboration revenue $150.5M (vs $0.7M).
- Cash, cash equivalents and marketable securities $273.3M as of March 31, 2023; plus $25M Novartis option payment received after quarter.
- Neurocrine Biosciences strategic collaboration: $175M upfront, up to $1.5B development milestones, $2.7B commercial milestones.
- Novartis exercised options for novel TRACER capsids: $25M payment, up to $600M milestones and royalties.
- Anti-tau antibody program VY-TAU01; IND filing on track for H1 2024. SOD1 program lead candidate now expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/0001558370-23-008652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/vygr-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer